i2O Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$3.5M
- Investors
-
14
i2O Therapeutics General Information
Description
Operator of a disruptive ionic liquid technology company designed to treat metabolic and inflammatory diseases. The company's platform employs proprietary ionic liquid technology to protect therapeutic molecules and enhance permeation across epithelial barriers, supports a pipeline of long-acting peptides including GLP-1, amylin, glucagon, and PYY analogs, and integrates orally deliverable GLP-1 combination assets, enabling pharmaceutical and biotechnology markets to improve patient adherence, reduce treatment burdens, and broaden access to biologic therapies.
Contact Information
Website
www.i2obio.comCorporate Office
- 610 Main Street
- Cambridge, MA 02139
- United States
Corporate Office
- 610 Main Street
- Cambridge, MA 02139
- United States
i2O Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A) | 18-Oct-2023 | $3.5M | Completed | Clinical Trials - General | ||
| 5. Early Stage VC (Series A) | 11-Oct-2022 | Completed | Clinical Trials - General | |||
| 4. Seed Round | 09-Apr-2020 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
i2O Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
i2O Therapeutics Comparisons
Industry
Financing
Details
i2O Therapeutics Competitors (2)
One of i2O Therapeutics’s 2 competitors is AI Proteins, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AI Proteins | Venture Capital-Backed | Boston, MA | ||||
| ProFound Therapeutics | Venture Capital-Backed | Cambridge, MA |
i2O Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
i2O Therapeutics Patents
i2O Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026152138-A2 | Injectable formulations comprising therapeutic compounds and methods of using thereof | Pending | 13-Jan-2025 | ||
| WO-2026152138-A3 | Injectable formulations comprising therapeutic compounds and methods of using thereof | Pending | 13-Jan-2025 | ||
| WO-2026152147-A1 | Methods of using injectable formulations comprising therapeutic compounds | Pending | 13-Jan-2025 | ||
| WO-2026044024-A1 | Compositions comprising combinations of pharmaceutically acceptable salts and other derivatives of glucagon-like peptide-1 receptor agonist and pharmaceutically acceptable salts and other derivatives of amylin analog, and uses thereof | Pending | 21-Aug-2024 | ||
| WO-2025264979-A1 | Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof | Pending | 21-Jun-2024 | A61P3/04 |
i2O Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
i2O Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hikma Ventures | Corporate Venture Capital | Minority | ||
| HM Venture Partners | Venture Capital | Minority | ||
| 7G Bioventures | Venture Capital | Minority | ||
| Cerity Partners Ventures | Corporate Venture Capital | Minority | ||
| Colorcon | PE-Backed Company | Minority |
i2O Therapeutics Investments (1)
i2O Therapeutics’s most recent deal was a Corporate Asset Purchase with Intarcia (cardio-metabolic pipeline assets). The deal was made on 29-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Intarcia (cardio-metabolic pipeline assets) | 29-Aug-2023 | Corporate Asset Purchase | Biotechnology |
i2O Therapeutics FAQs
-
When was i2O Therapeutics founded?
i2O Therapeutics was founded in 2019.
-
Where is i2O Therapeutics headquartered?
i2O Therapeutics is headquartered in Cambridge, MA.
-
What is the size of i2O Therapeutics?
i2O Therapeutics has 6 total employees.
-
What industry is i2O Therapeutics in?
i2O Therapeutics’s primary industry is Drug Discovery.
-
Is i2O Therapeutics a private or public company?
i2O Therapeutics is a Private company.
-
What is the current valuation of i2O Therapeutics?
The current valuation of i2O Therapeutics is .
-
What is i2O Therapeutics’s current revenue?
The current revenue for i2O Therapeutics is .
-
How much funding has i2O Therapeutics raised over time?
i2O Therapeutics has raised $53.5M.
-
Who are i2O Therapeutics’s investors?
Hikma Ventures, HM Venture Partners, 7G Bioventures, Cerity Partners Ventures, and Colorcon are 5 of 14 investors who have invested in i2O Therapeutics.
-
Who are i2O Therapeutics’s competitors?
AI Proteins and ProFound Therapeutics are competitors of i2O Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
